<DOC>
	<DOCNO>NCT00821990</DOCNO>
	<brief_summary>Because well-designed , randomize , control clinical trial lack patient advanced gastric cancer ( AGC ) , randomly allocate patient treatment accord preference may influence trial validity , investigator employ patient preference randomize trial design compare efficacy second-line chemotherapy best supportive care .</brief_summary>
	<brief_title>Second-line Therapy Versus Supportive Care Pretreated Advanced Gastric Cancer</brief_title>
	<detailed_description>Fluoropyrimidine and/or platinum-based chemotherapy regard standard first-line treatment AGC patient show superiority term response rate time disease progression compare 5-FU monotherapy combination phase III trial . Despite lack evidence benefit associate administer salvage chemotherapy , common practice offer chemotherapy AGC patient first-line failure . For patient fail fluoropyrimidine platinum , taxanes ( paclitaxel docetaxel ) irinotecan evaluate extensively second-line setting . Currently , evidence SLC patient AGC result substantial prolongation survival potential toxicity treatment .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>age 75 year younger advance gastric cancer ECOG performance status 0 1 previous failure chemotherapy fluoropyrimidine platinum adequate major organ function severe concurrent illness and/or active infection previously treat taxanes irinotecan active CNS metastasis pregnant lactate woman recover prior treatment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Failed previous chemotherapy</keyword>
</DOC>